Cognitive and Functional Assessment in Clinical Trials of Alzheimer’s Disease and Its Precursors 2016 Autumn Workshop

Co-chairs:  Holly Posner, MD / Philip Harvey, PhD

Objective: Continue and fine-tune our discussion on the ideal prevention trial design by having several additional key experts attend: Dorene Rentz, Marwan Sabbagh, and Jeff Kaye. They will provide expertise in performance to biomarker convergence in preclinical AD, assessment and prevention of AD in individuals with Down’s Syndrome, and innovative naturalistic outcomes assessments in early prevention trials, respectively.

This meeting will add on to the information presented in our previous two documents, now in review at ICNS:
—Outcomes Assessment in Clinical Trials of Alzheimer’s disease and Its Precursors: Readying for Short-term
—Long-term Clinical Trial Needs and Performance-Based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

Autumn workshop deliverable: Paper with content derived from the 2016 February Working group dinner and Autumn 2016 Workshop.